Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Sideman

Vascular Surgery San Antonio, TX Medical Doctor

NPI 1386614774 CMS profile 334537

8300 Floyd Curl Dr Fl 4, San Antonio, TX 78229

Open in the dashboard

General payments

$11,123

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$30,906 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Matthew Sideman of San Antonio, TX is reported in the CMS Open Payments database as having received $11,123 across 204 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $30,906 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 70th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,772 36
2024 General $1,608 29
2023 General $1,657 43
2022 General $3,172 44
2021 General $1,050 24
2020 General $447 15
2019 General $417 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Sideman
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Matthew Sideman were reported at $2,772. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Matthew Sideman Vascular Surgery median Middle half National median
2019 $417 $796 $226–$2,363 $163
2020 $447 $348 $118–$1,110 $114
2021 $1,050 $471 $158–$1,421 $132
2022 $3,172 $725 $222–$2,183 $149
2023 $1,657 $836 $257–$2,440 $160
2024 $1,608 $909 $252–$2,619 $164
2025 $2,772 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $2,488 26 payments
  2. Reflow Medical Inc $1,523 10 payments
  3. Medtronic, Inc. $1,187 13 payments
  4. Bard Peripheral Vascular, Inc. $959 31 payments
  5. Cook Medical LLC $851 23 payments
  6. Endologix, Inc. $473 6 payments
  7. AngioDynamics, Inc. $418 9 payments
  8. Boston Scientific Corporation $332 6 payments
  9. Janssen Pharmaceuticals, Inc $244 10 payments
  10. Veryan Medical Incorporated $220 2 payments
  11. Other $2,427 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,479 192 payments
  2. Travel and Lodging $2,644 12 payments
Products named General payments · program years 2019–2025
  1. GORE TAG Thoracic Endoprosthesis $1,347 7 payments
  2. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $457 10 payments
  3. AURYON LASER SYSTEM 100-120 VAC $418 9 payments
  4. ENDURANT IIS $383 4 payments
  5. ENDOCROSS Device $274 3 payments
  6. Torus Stent Graft System $274 3 payments
  7. Valiant Captivia $272 3 payments
  8. XARELTO $244 10 payments
  9. Zenith Spiral-Z $237 2 payments
  10. LUTONIX $230 5 payments
  11. Other $5,631 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

86

Median for Vascular Surgery: 122

Drug cost

$927

Median for Vascular Surgery: $14,135

Branded share of claims

77.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 67 $652
Cilostazol Generic 19 $275

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 117 billing codes

Paid by Medicare

$127,074

Medicare's payments for the services billed

Medicare patients

339

Average age 74

Services billed

832

154 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 51%
Diabetes 50%
Chronic kidney disease 47%
Heart failure 30%
Atrial fibrillation 24%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record